Stimuli-Responsive Amphiphilic Pillar[n]arene Nanovesicles for Targeted Delivery of Cancer Drugs

Cancer chemotherapeutics face several challenges, including uncontrollable drug release, off-target toxic effects, and poor bioavailability. Recently, supramolecular nanovesicles, such as calix­[n]­arenes (CXs), cyclodextrins (CDs), cucurbiturils (CBs), and pillar­[n]­arenes (PRs), have attracted at...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS omega 2021-10, Vol.6 (40), p.25876-25883
Hauptverfasser: Fahmy, Sherif Ashraf, Ramzy, Asmaa, Saleh, Basma M, El-Said Azzazy, Hassan Mohamed
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Cancer chemotherapeutics face several challenges, including uncontrollable drug release, off-target toxic effects, and poor bioavailability. Recently, supramolecular nanovesicles, such as calix­[n]­arenes (CXs), cyclodextrins (CDs), cucurbiturils (CBs), and pillar­[n]­arenes (PRs), have attracted attention as potential smart nanocarriers for chemotherapeutics because of their exceptional cavities that can achieve high encapsulation capacity and accommodate both hydrophilic and hydrophobic drugs. In addition, they can be functionalized with different stimuli-responsive groups, which facilitate controlled drug release. Supramolecular nanovesicles, loaded with drugs and decorated with stimuli-responsive targeting moieties, are designed by either host–guest complexation or self-assembly of amphiphilic cavitands. Pillar­[n]­arenes, in particular, are novel supramolecular host molecules that have recently been employed in cancer targeted drug delivery because of their symmetric pillar-shaped structure, simplicity of functionalization, and biocompatibility. This review summarizes state-of-the-art strategies for developing single or multiple stimuli-responsive pillar­[n]­arene nanovesicles for effective cancer treatment.
ISSN:2470-1343
2470-1343
DOI:10.1021/acsomega.1c04297